伊尼妥单抗(Inetetamab) - 药物靶点：HER2_在研适应症：乳腺癌，HER2阳性乳腺癌，肿瘤_专利_临床

概要

基本信息

药物类型

生物类似药、单克隆抗体

别名

Cipterbin、Trastuzumab biosimilar、302H

+ [3]

靶点

HER2

作用机制

HER2拮抗剂(受体蛋白酪氨酸激酶 erbB-2拮抗剂)、ADCC(抗体依赖的细胞毒作用)

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症

乳腺癌HER2阳性乳腺癌肿瘤

非在研适应症-

原研机构

三生国健药业（上海）股份有限公司

在研机构

三生国健药业（上海）股份有限公司

3SBio, Inc.

非在研机构-

最高研发阶段批准上市

首次获批日期

中国 (2020-06-17),

乳腺癌

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 18481L

当前序列信息引自: *****

Sequence Code 44772H

当前序列信息引自: *****

关联

21

项与伊尼妥单抗相关的临床试验

NCT06641544 / Recruiting临床4期IIT

The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer

This study is to explore the efficacy and safety of the first-line treatment of HER2 positive recurrent/metastatic breast cancer with Inetetamab combined with Pertuzumab or Pyrotinib combined with chemotherapy, hoping to have better clinical benefits and provide a new treatment mode for targeted treatment.

开始日期2024-10-17

申办/合作机构

中山大学

NCT06578299 / Not yet recruiting临床4期IIT

The Real World Study of First Line Treatment of HER2 Positive Recurrent/Metastatic Breast Cancer With Inetetamab Combined With Paclitaxel With/Without Pertuzumab（INTPOWER）

This study is designed to comprehensively evaluate the HER2 positive recurrent/metastatic breast cancer patients in the real world who receive the combination of Inetetamab and Paclitaxel ± Pertuzumab, including basic characteristics, efficacy and safety. The results of this study are helpful to further understand the efficacy and safety of HER2 positive patients with recurrent/metastatic breast cancer who receive the combination of Inetetamab and Paclitaxel ± Pertuzumab in the first line, and help clinical decision-making.

开始日期2024-08-30

申办/合作机构

复旦大学

NCT05980208 / Not yet recruitingN/AIIT

A Real-world Study of Inetetamab for First-line Treatment of HER2-positive Inoperable Locally Advanced or Relapsed Metastatic Breast Cancer

This is a prospective, multicenter, real-world study aimed at evaluating the efficacy and safety of inetetamab+chemotherapy or inetetamab+pyrotinib+chemotherapy or inetetamab+pertuzumab+chemotherapy in the treatment of HER2 positive inoperable locally advanced or recurrent metastatic breast cancer. The research results will provide new targeted treatment strategies for HER2 positive breast cancer patients.

开始日期2023-09-01

申办/合作机构

湖南省肿瘤医院

100 项与伊尼妥单抗相关的临床结果

登录后查看更多信息

100 项与伊尼妥单抗相关的转化医学

登录后查看更多信息

100 项与伊尼妥单抗相关的专利（医药）

登录后查看更多信息

22

项与伊尼妥单抗相关的文献（医药）

2024-12-01·JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY

Role of PD‐1 in modulating IFN‐γ‐CXCL9/10‐CXCR3 signaling in breast cancer

Article

作者: Kong, Yan ; Hong, Lei ; Li, Man ; Dong, Qian ; Hu, Zexian ; Huang, Fang ; Cui, Yanzhi ; Zheng, Xuan

Abstract:

Breast cancer represents a significant health burden globally, necessitating ongoing advancements in treatment strategies for improved patient outcomes. Immunotherapy, particularly targeting immune checkpoints like programmed death‐1 (PD‐1), has emerged as a promising approach in cancer therapy. This study focuses on elucidating the role of PD‐1 in modulating the IFN‐γ‐CXCL9/10‐CXCR3 signaling axis within the breast cancer microenvironment. By investigating the synergistic effects of PD‐1 inhibitors in combination with Inetetamab, our research aims to uncover novel therapeutic targets for enhancing immunotherapy efficacy in breast cancer. Through comprehensive experimental analysis, we seek to deepen our understanding of the intricate molecular mechanisms underlying immune regulation in breast cancer, thereby paving the way for more effective and sustainable treatment strategies. Ultimately, our study endeavors to establish a robust theoretical framework that can guide the development of innovative clinical interventions, aiming for improved outcomes in breast cancer patients.

2024-11-06·Journal of Translational Internal Medicine

Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial

Article

作者: Zheng, Yabing ; Wang, Xiaojia ; Chen, Zhanhong ; Gan, Lu ; Xie, Ning ; Yang, Xiuli ; Wang, Xinshuai ; Huang, Jian ; Chen, Yuru ; Ouyang, Quchang ; Yang, Hua ; Chen, Shaoping ; Cao, Wenming ; Shao, Xiying

Abstract:

Objective:

We aimed to investigate the pharmacokinetics, safety, efficacy, and immunogenicity of different dosing regimens (weekly and every three weeks) of inetetamab in combination with vinorelbine in human epidermal growth factor receptor 2 (HER2)+ patients with metastatic breast cancer who had received one or more chemotherapy regimens.

Methods:

HER2+ patients with metastatic breast cancer who had received one or more chemotherapy regimens were included. Eligible patients received inetetamab administered weekly or every three weeks in combination with vinorelbine injection chemotherapy. Pharmacokinetics, safety, efficacy, and immunogenicity were compared between the groups.

Results:

Sixty HER2+ patients were randomized into a single-week administration group ( n = 29) and a three-week administration group ( n = 31). After the final dose in the single-week administration group and the three-week administration group, the mean Cmax values were 79.773 μg/mL and 146.083 μg/mL; the mean Cmin values were 30.227 μg/mL and 11.926 μg/mL; the mean AUCtau values were 7328.443 μg·h/mL and 22647.101 μg·h/mL; and the mean Cav values were 43.622 μg/ mL and 44.935 μg/mL, respectively. The best overall response (BOR) rates at 24 weeks and unconfirmed BOR rates at 24 weeks were both 40.7% in the single-week dosing group and 40.7% in the three-week dosing group, and the 24-week confirmed disease control rates (DCRs) were 88.9% and 81.5%, respectively. The incidence of adverse events (AEs) was generally consistent across all levels.

Conclusion:

There were slight differences in the mean Cmax, Cmin, AUCtau and Cav between the three-week dosing group and the single-week dosing group, and the mean steady-state concentrations of Cav were comparable; however, there were no differences in efficacy, safety or immunogenicity between the two groups.

2024-10-01·Cancer Innovation

Inetetamab combined with sirolimus and chemotherapy for the treatment of HER2‐positive metastatic breast cancer patients with abnormal activation of the PI3K/Akt/mTOR pathway after trastuzumab treatment

Article

作者: Sun, Xiaoying ; Sun, Jing ; Wang, Mengyuan ; Zhao, Jiuda ; Cai, Li ; Li, Qiao ; Shi, Yehui ; Li, Chenghui ; Ma, Fei ; Liu, Feng ; Lv, Dan

Abstract:

Background:

We explored the efficacy and safety of inetetamab combined with sirolimus and chemotherapy for the treatment of human epidermal factor receptor 2 (HER2)‐positive metastatic breast cancer patients with abnormal activation of the PI3K/Akt/mTOR (PAM) pathway after trastuzumab treatment.

Methods:

For this prospective multicenter clinical study, HER2‐positive metastatic breast cancer patients with PAM pathway mutations confirmed by histology or peripheral blood genetic testing were enrolled from July 2021 to September 2022. Patients were randomly assigned to a trial or control group. The patients in the trial group received inetetamab combined with sirolimus and chemotherapy, while the control group patients received pyrotinib and chemotherapy. The RECIST v1.1 standard was used to evaluate efficacy. Descriptive statistics were used to summarize the clinicopathological features, and the Kaplan–Meier method was used to generate survival curves. The log‐rank test was used to compare progression‐free survival (PFS) between the two groups.

Results:

A total of 59 HER2‐positive metastatic breast cancer patients with abnormal activation of the PAM pathway were included, of which 37 received inetetamab combined with sirolimus and chemotherapy treatment and 22 received pyrotinib and chemotherapy treatment. The median PFS was 4.64 months in the inetetamab group and 5.69 months in the pyrotinib group, with no statistically significant difference (p = 0.507). The objective response rates were 27.3% for the inetetamab group and 29.4% for the pyrotinib group. The safety assessment indicated that the adverse event (AE) incidences were 86.1% (31/36) in the inetetamab group and 78.9 (15/19) in the pyrotinib group, with 9 (25%) and four (21.1%) Grade 3/4 AEs in the inetetamab and pyrotinib groups, respectively.

Conclusions:

For metastatic HER2‐positive breast cancer patients with abnormal PAM pathway activation and previous trastuzumab treatment, the combination of inetetamab with sirolimus and chemotherapy is equivalent to the combination of pyrotinib and chemotherapy. Therefore, this regimen could be a treatment option for PAM pathway‐activated metastatic HER2‐positive breast cancer patients.

73

项与伊尼妥单抗相关的新闻（医药）

2024-12-06

·三生国健

2024 ESMO ASIA | 一项伊尼妥单抗一线治疗晚期HER2阳性胃癌患者研究亮相

整理：肿瘤资讯来源：肿瘤资讯 2024年欧洲肿瘤内科学会亚洲年会（ESMO Asia 2024）将于12月6日至8日在新加坡举行。此次会议旨在展示和讨论亚洲地区肿瘤学领域的最新临床科研进展，进一步推动学术交流与共同进步。其中，一项关于伊尼妥单抗用于HER2阳性晚期胃癌一线治疗的研究结果将在会议上亮相[1]。该研究显示，伊尼妥单抗在HER2阳性晚期胃癌的一线治疗中，整体疗效与曲妥珠单抗相当。该项研究的结果已发表在World Journal of Gastroenterology 2024年刊上[2]。摘要号：158P 研究题目 Updated Efficacy and Safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric cancer SOX方案联合伊尼妥单抗作为HER2阳性晚期胃癌一线治疗的有效性和安全性数据更新研究背景 HER2阳性晚期胃癌患者的预后较差。目前，曲妥珠单抗联合化疗是该类患者的一线标准治疗方案。伊尼妥单抗是我国首个自主研发的创新抗HER2单克隆抗体，其Fab段与曲妥珠单抗相同，而Fc段经过两个氨基酸位点的修饰，以增强抗体依赖性细胞介导的细胞毒作用（ADCC）效应，并降低免疫原性和不良反应。前期基础研究发现，在胃癌治疗中，伊尼妥单抗与TKI药物的联合使用能够产生协同的抗肿瘤效果。本研究旨在评估临床应用中伊尼妥单抗联合SOX方案（S-1加奥沙利铂）作为HER2阳性晚期胃癌一线治疗的疗效和安全性。研究方法本研究纳入38例HER2阳性晚期胃癌或胃食管交界腺癌患者，并将其随机分为两组：一组接受伊尼妥单抗联合SOX方案治疗，另一组接受曲妥珠单抗联合SOX方案治疗。经过4至6个周期的治疗后，病情稳定的患者继续接受维持治疗。本研究的主要终点是PFS和总生存期（OS），次要终点包括客观缓解率（ORR）、疾病控制率（DCR）以及不良事件（AEs）的发生情况。研究设计研究结果共37例患者完成了试验（伊尼妥单抗组18例，曲妥珠单抗组19例）。主要研究终点方面，伊尼妥单抗组与曲妥珠单抗组的中位PFS分别为8.5个月和7.3个月，两组的中位OS分别为15.3个月和14.3个月，ORR分别为50%和42%，DCR分别为88.9%和94.7%，这些指标均未显示出统计学上的显著差异。常见的AEs包括血液学毒性和胃肠道症状。≥3级AEs在伊尼妥单抗组中的发生率为56%，而在曲妥珠单抗组中为47%，两组之间无统计学差异。研究结果（A：PFS；B：OS）参考文献： [1]. Kong Y, Dong Q, Jin P, et al. Updated Efficacy and Safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric cancer. ESMO ASIA.2024.158P.[2]. Kong Y, Dong Q, Jin P, Li MY, Ma L, Yi QJ, Miao YE, Liu HY, Liu JG. Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer. World J Gastroenterol 2024; 30(40): 4367-4375.[3]. Open Life Sci. 2023 Jan 10;18(1):20220535.doi: 10.1515/biol-2022-053.

临床结果抗体药物偶联物

2024-12-04

·药智网

第4款「帕妥珠单抗类似药」申报上市

12月4日，复宏汉霖帕妥珠单抗注射液的上市申请获得NMPA受理，这也是第4款申报上市的帕妥珠单抗类似药。此前，齐鲁制药、正大天晴、博锐生物陆续申报帕妥珠单抗类似药。图片来源：医药笔记罗氏的曲妥珠单抗、帕妥珠单抗分别靶向HER2的不同表位，并开发了复方制剂已经上市。曲妥珠单抗已经有复宏汉霖、博锐生物、三生国健（伊尼妥单抗，序列不完全相同按2类新药申报）获批上市。安科生物、正大天晴、齐鲁制药也已经递交上市申请。帕妥珠单抗目前仅齐鲁制药、正大天晴进入报上市阶段。 <总结> 尽管国内生物类似药的竞争异常激烈，但能做到国际化的屈指可数，复宏汉霖的曲妥珠单抗类似药已经在欧盟、美国获批上市，前不久完成了美国首批发货。友情推荐：医药行业深度技术内容，点击“博药”查看详情~ 来源 | 医药笔记（药智网获取授权转载）撰稿 | Armstrong 责任编辑 | 八角声明：本文系药智网转载内容，图片、文字版权归原作者所有，转载目的在于传递更多信息，并不代表本平台观点。如涉及作品内容、版权和其它问题，请在本平台留言，我们将在第一时间删除。商务合作 | 王存星 19922864877（同微信）阅读原文，是受欢迎的文章哦

生物类似药上市批准

2024-12-04

·医药笔记

复宏汉霖：帕妥珠单抗申报上市

▎Armstrong 2024年12月4日，复宏汉霖帕妥珠单抗注射液的上市申请获得NMPA受理，这也是第4款申报上市的帕妥珠单抗类似药。刺秦，齐鲁制药、正大天晴、博锐生物陆续申报帕妥珠单抗类似药。罗氏的曲妥珠单抗、帕妥珠单抗分别靶向HER2的不同表位，并开发了复方制剂已经上市。曲妥珠单抗已经有复宏汉霖、博锐生物、三生国健（伊尼妥单抗，序列不完全相同按2类新药申报）获批上市。安科生物、正大天晴、齐鲁制药也已经递交上市申请。帕妥珠单抗目前仅齐鲁制药、正大天晴进入报上市阶段。总结尽管国内生物类似药的竞争异常激烈，但能做到国际化的屈指可数，复宏汉霖的曲妥珠单抗类似药已经在欧盟、美国获批上市，前不久完成了美国首批发货。 Armstrong技术全梳理系列 GPRC5D靶点全梳理； CD40靶点全梳理； CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向； Claudin 6靶点全梳理； Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇； CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理； Ambrx技术全梳理； Vir Biotech技术全梳理； Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；科望医药技术全梳理2.0；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理； Momenta技术全梳理； NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

抗体药物偶联物生物类似药

100 项与伊尼妥单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
乳腺癌	中国	三生国健药业（上海）股份有限公司	2020-06-17

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HER2阳性乳腺癌	临床2期	中国	三生国健药业（上海）股份有限公司	2023-03-24
肿瘤	临床2期	中国	3SBio, Inc.	2022-01-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05749016 (ESMO2024) 人工标引	临床2期	HER2阳性乳腺癌新辅助 HER2 Positive	39	Inetetamab + Pertuzumab + Paclitaxel + Carboplatin (TCbIP)	(積鹽襯壓鑰廠膚艱獵範) = 膚淵齋鏇觸襯鑰齋鏇壓醖夢鹹獵鹹鏇鹽鏇壓獵 (衊鬱遞範憲壓鹹鏇鬱顧 ) 更多	积极	2024-09-16
				Neoadjuvant treatment with TCbIP	(積鹽襯壓鑰廠膚艱獵範) = 顧膚積醖簾齋壓齋選膚醖夢鹹獵鹹鏇鹽鏇壓獵 (衊鬱遞範憲壓鹹鏇鬱顧 )
NCT05749016 (Pubmed) 人工标引	临床2期	晚期 HER2 阳性乳腺癌新辅助 HER2 Positive	-	Inetetamab + Pertuzumab + Taxanes + Carboplatin (TCbIP)	鬱簾鹹獵遞積繭齋繭觸(憲齋鹽遞淵製構築鏇憲) = 製選蓋簾糧衊餘醖願製觸憲鹽製顧蓋淵膚壓齋 (夢醖蓋鹹醖憲膚繭醖範 ) 更多	积极	2024-07-22
				Trastuzumab + Pertuzumab + Taxanes + Carboplatin (TCbHP)	鬱簾鹹獵遞積繭齋繭觸(憲齋鹽遞淵製構築鏇憲) = 鑰選構膚鹹衊憲餘艱選觸憲鹽製顧蓋淵膚壓齋 (夢醖蓋鹹醖憲膚繭醖範 ) 更多
NCT05749016 (ASCO2024) 人工标引	临床2期	晚期 HER2 阳性乳腺癌新辅助 HER2 Positive	28	Inetetamab + Pertuzumab + Paclitaxel + Carboplatin (TCbIP)	鏇簾遞膚築獵鬱廠壓壓(糧鏇窪膚廠窪艱餘簾艱) = 艱積艱蓋積齋獵窪觸簾構築糧鏇餘網襯糧鹽淵 (醖壓觸遞淵衊齋範壓襯 ) 更多	积极	2024-05-24
				Trastuzumab + Pertuzumab + Paclitaxel + Carboplatin (TCbHP)	鏇簾遞膚築獵鬱廠壓壓(糧鏇窪膚廠窪艱餘簾艱) = 膚鏇鏇餘顧願醖鹽鹽簾構築糧鏇餘網襯糧鹽淵 (醖壓觸遞淵衊齋範壓襯 ) 更多
ASCO2024	N/A	HER2阳性转移性乳腺癌 HER2-positive	500	Inetetamab	窪鏇鹹顧範醖築醖夢廠(鬱醖夢築鬱壓窪獵範製) = 31.4% 願醖糧廠製願鹹鹹蓋鹽 (構鏇餘繭顧製憲淵構醖 ) 更多	积极	2024-05-24
				Inetetamab+Tyrosine Kinase Inhibitors+Chemotherapy
ASCO2024	N/A	晚期 HER2 阳性乳腺癌二线 HER2-positive	99	Inetetamab combined with pyrotinib plus albumin-bound paclitaxel	衊鬱艱築觸獵齋衊蓋繭(獵簾鏇範鹽遞鬱鏇積艱) = 醖獵壓廠範淵構願餘壓選顧鏇製願餘襯窪積繭 (鏇選鹽積繭窪觸糧廠願, 13.6 ~ 15.8) 更多	积极	2024-05-24
				Inetetamab combined with pyrotinib plus chemotherapy	衊鬱艱築觸獵齋衊蓋繭(獵簾鏇範鹽遞鬱鏇積艱) = 築積衊蓋襯糧製衊鏇製選顧鏇製願餘襯窪積繭 (鏇選鹽積繭窪觸糧廠願, 9.6 ~ 10.9) 更多
NCT05823623 (Pubmed) 人工标引	临床2期	HER2阳性乳腺癌 HER2 Positive	30	Inetetamab + Pyrotinib + Oral Vinorelbine	遞範蓋顧餘餘積網顧艱(繭艱壓餘壓艱網鏇窪遞) = 鬱築範膚鏇襯鏇醖獵願鬱顧簾繭夢鹽鬱淵鏇廠 (醖膚蓋簾襯鏇願鬱鏇選, 4.15 ~ 13.12) 更多	积极	2024-01-01
ESMO_ASIA2023	N/A	HER2阳性转移性乳腺癌 HER2-positive	77	Inetetamab combined with pyrotinib and vinorelbine	鑰鹽夢蓋積鬱遞構蓋顧(觸積艱襯選壓鹽壓範鬱) = occurring in 36 patients (46.8%) 願鹽鏇襯夢廠壓觸鏇願 (構網選餘衊蓋糧選範築 ) 更多	积极	2023-12-02
IPU (ESMO2023) 人工标引	临床2期	HER2阳性乳腺癌一线 \| 二线 HER2 positive	29	Inetetamab+ pyrotinib+utidelone	齋獵窪膚鹽鏇願壓蓋壓(膚願構壓膚鬱製築顧遞) = 築選構獵觸糧窪餘鏇獵壓鏇鑰選憲繭襯窪鬱顧 (顧選艱積淵窪糧廠夢鑰 ) 更多	积极	2023-10-21
ESMO2023 人工标引	N/A	HER2阳性转移性乳腺癌二线 HER2 positive	89	Vinorelbine + Inetetamab + Pyrotinib	繭憲壓製壓餘鹽遞鬱憲(網憲範網衊齋遞觸繭糧) = 艱鹹憲鏇齋顧夢糧範範觸顧齋膚網醖鏇壓齋膚 (築夢醖醖築願膚願鹹鹽 )	积极	2023-10-21
				Vinorelbine + Inetetamab + Pyrotinib (second-line treatment)	簾範築築齋積膚繭築艱(繭簾鹽艱鬱壓鏇餘淵艱) = 憲衊鏇積齋製蓋糧範遞餘鹽網齋製鏇築餘鹹鹹 (窪積憲築願壓壓鹹範獵 ) 更多
NCT05749016 (ESMO2023) 人工标引	临床2期	局部晚期乳腺癌新辅助 HER2-positive	23	Inetetamab + Pertuzumab + Paclitaxel + Carboplatin	壓積鬱積艱衊構繭蓋醖(艱觸衊窪膚壓簾襯艱夢) = 襯鏇淵蓋願製觸窪蓋網鹹築鏇鏇願夢窪艱簾製 (觸鏇鑰繭糧艱簾願醖鑰 )	积极	2023-10-21
				Inetetamab + Pertuzumab + Paclitaxel + Carboplatin (completed the study treatment and surgery)	糧鏇鹹顧範範襯鑰願顧(觸構糧窪積夢衊築鏇繭) = 鹹獵鹽遞繭窪壓遞鑰醖願襯膚廠鹽選醖鏇壓糧 (餘遞鬱築襯繭蓋築蓋淵 ) 更多